04/05/2026
Epigral has recorded its most successful quarter to date, delivering ₹736 Crore in revenue in Q4FY26. 📈
Key drivers of this 22% sequential revenue growth were strong volume growth. Our diversified product portfolio continues to provide resilience amid geopolitical uncertainties, with the Derivatives & Specialty business now contributing 54% to our overall revenue mix.
Looking forward, our ongoing capex projects for Epichlorohydrin and CPVC expansion remain perfectly on budget and schedule. With these facilities nearing completion, we are well-positioned to deliver consistent long-term value for our stakeholders.
(Financial results, Quarterly results, Business growth, Chemical manufacturer)